Since BZNE sold all its assets and Cocrystal only has a pipeline that is in early phase 1 trials, as far as I can see, where will this new entity get revenues from over the next few quarters? If/when they raise revenue via an equity offering,secondary, pref. stock etc. will that not devalue the present stockholders? Does anybody have any info? I like Dr.Frost and have made money with him as my previous posts state but I can find no solid info on this trade.
They seem to be the smart ones. They get to cover with a nice profit, longs get no meaningful stock lift, and they [short traders] can reestablish a short position prior to the next equity offering assuring another profit. Longs need proactive management, A WHITE KNIGHT, or they will be trashed again IMO
analyst or brokerage buy rating takes this stock to $20_30 dollars. IMO we could see this if/when cgix announces one big contract signing. If and when they announce insurance reimbursement this stock will see triple digits in the coming years.
last time I looked she has the money and a management team that has accomplished more with less than the past and current MELA management teams.... IMO she would be improvement.
days thanks Dr. Frost and companions. Forgot a stop limit and got sold out @ $.71. No compaints. My question going forward is, does Cocrystal have anything that is revenue producing over the next year or two to bring to the merger? From what I can see , which is very little, everything they presently show is in early/late phase one. Any insights/opinions?
No, not their PR just what almost every Derm, analyst, professional, etc, that has seen and used Melafind has to say about it. If I'm not mistaken even a biased and ill equipped FDA approved it.
It's at the point that MELA current shareholders only chance to turn a profit prior to the next equity offering is if insurance reimbursement can/will happen within 1 year. Currently the device will be used by people that can afford to pay, institutions, wealthy patients, hospitals, etc. but that will not pay the bills and MELA needs revenue now, it is currently a one trick pony. Waiting and hoping that the world will wake up and use the device is a dream. Without insurance reimbursement management will continue to sell shares in a slow chinese water torture fashion and current shareholders will be liquidated slowly while management collects their salaries and Doctors/patients continue barbaric procedures, etc.
MELA needs a white knight that will invest $40-50 million cash, clean house, set up strategic partnerships with cancer institutes, device suppliers, finance and insurance people and get this device in every hospital, cancer center, university, Derm. office,, etc and make this device the diagnostic standard and maybe with insurance reimbursement they become profitable in a couple of years. Going to shows, conference etc. DOES NOT PRODUCE REVENUES. We have all seen over the last few years how everybody loves the device BUT will not commit without the insurance companies commitment. Most/all patients will not spend their own money but will biopsy instead. Doctors will chose the path of least resistance and on and on and on..... We need somebody like Dr. Frost or Poppajohn, etc. with a proven/aggressive track record, we seem to have a management team of tired retreads @ this time, or we are (&^%%&*(#$%$ IMHO
and no dramatic increase in revenues anticipated by management in the near future [ 2-6 months]. Has anybody done a pro forma showing when MELA will need to raise money thru an equity or secondary offering? If management isn't increasing revenues can they possibly borrow money in the credit markets? After the last CC did management give any indication of any possible catalyst that could increase the stock price in the coming quarters?
Why? I have owned opko for awhile now, since $7.5 ps aprx. I picked up a nice return with sfes recently and started to dabble with bzne. I have followed the good Dr. since Ivax days and have made some money. But why would you not want to own cgix while it is a $85 million market cap company that is ready to skyrocket. It is first to market with a soon to be industry standard product that is accepted by every major cancer center and patented? Insurance company reimbursement is around the corner as test is more desirable an less invasive than biopsies and as cost effective? CGIX pipeline is already at the revenue generation point with certain products. CGIX is in a $billion dollar revenue generating market with no near term competitors. Unless management is totally out to lunch, which I do not believe, what is not to like?
CGIX presently has a market cap of aprox. $85m. New lung cancer cases, alone, aprox 1.6 million p/year. If CGIX did a test on 10% @ the stated $500+ p/test that's 160000 x 500 = $80m, if, industry standard, possible 75%+ with insurance reimbursement? . CGIX is first to market and affiliated with almost every major Cancer Institute, it has the potential to be the industry standard. The diagnostic market has the ability to generate $billions of dollars in revenue. The more I look at this company the more stock I buy. IMO this company will fund a lot of retirement and educational needs of early investors.
GS downgrades PM @$89 and puts a price target of $95. Wanna bet the GS trading desk was shorting PM the last few days @ $90+ and is covering today @ $86 and holds for 2-4 quarters collecting appreciation and a 4%+ dividend. That's how their trading desk makes money in my opinion...............
There is not much of a float. The company seems well run and defined by management. They are first to market in a field that is wide open. There current client list is a whos who of leading cancer institutes. Insurance reimbursement is the large catalyst and could take awhile, not sure how far along they are in process and last CC did not really answer clearly. IMO the company should be trading around $20 ps within a quarter or two, possibly sooner, unless they raise money thru another secondary or equity offering. With insurance reimbursement the sky's the limit..........JMO
announce news regarding merger, reverse sale, OR WHATEVER that odd statement management released in an effort to explain that asset sale?. What effect does possible lawsuit have on those plans? The asset sale was for stock, half in escrow can the other half be sold to raise money, when does it close? There sure are a lot more questions, why no comments from management other than the paragraph that raised more questions than answers? This doesn't seem to have Dr. Frosts hand guiding it at this time, IMO .
I wasn't commenting on your fully funded trades but on the fact that blocks of 289k are large for a company with average trading volume of 348k. Regarding green day my comment in capital letters was ' at the moment'.
Your call on the direction of MELA stock price has been correct so far but your ability to read seems a little suspect at the moment. Why such negativity ?
The float is very small and Pappajohn owns over 20%. The company just did a secondary that almost doubled the float a few weeks ago for $14 ps. Short traders can move this price alot by trading amounst themselves. This company is a spec. investment and will trade wildly from week to week IMO. After the secondary has a chance to find a permanent home we should approach $20ps. IMO...........
Over 1 million shares before 1pm, close to 3x daily ave. already on no posted news. Two large share blocks 289k plus around 12:45. Nothing posted @ SEC yet. AND MELA TRADING IN THE GREEN AT THE MOMENT. Anybody heard/seen any news?